Brexucabtagene autoleucel showed comparable efficacy outcomes in patients aged 60 to 69 with relapsed/refractory B-cell acute ...

Virginia G. Kaklamani, MD, DSc, discusses how effective elacestrant (Orserdu) is in CDK4/6 inhibitor-naive estrogen ...

A study of 9,146 patients found no OS difference among first-line CDK4/6 inhibitor combinations for HR+/HER2- metastatic ...

In a meta-analysis, second-generation BTK inhibitors were linked to a significantly low incidence of atrial fibrillation, ...

Ciltacabtagene autoleucel achieved a 100% complete response rate in patients with high-risk smoldering multiple myeloma, as ...

Adverse events associated with ponatinib in CML and ALL were shown to have decreased significantly since its approval, ...

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative ...

Abdulraheem Yacoub, MD, discusses option for patients with myelodysplastic syndromes and red blood cell transfusion dependence.